UBE2N作为肺腺癌的新预后和治疗生物标志物
Haofeng Yin1, Yibo Xue2, Chen Wang3
1Institute of Immunology, School of Basic Medicine, Naval Medical University, Shanghai, China.
Frontiers in immunology
|August 27, 2025
概括
UBE2N是肺腺癌 (LUAD) 的新型预后生物标志物. 抑制UBE2N可能会抑制LUAD的进展并提高治疗的有效性,为这种疾病提供新的治疗策略.
科学领域:
- 癌症学
- 分子生物学
- 生物标志物发现
背景情况:
- 由于缺乏有效的生物标志物和可变的治疗反应,肺腺癌 (LUAD) 构成重大健康挑战.
- 确定可靠的生物标志物对于改善患者的治疗结果和指导治疗策略至关重要.
研究的目的:
- 确定用于预测LUAD患者预后和治疗反应的新生物标志物.
- 评估已识别的生物标志物作为LUAD干预的治疗目标的潜力.
主要方法:
- 使用公共数据库选关键预后基因,然后进行外部验证.
- 使用临床病理指标分析了UBE2N在LUAD进展中的预后作用.
- 进行功能丰富,免疫微环境分析和生物信息学方法来评估UBE2N在治疗敏感性的作用.
- 通过免疫组织化学,细胞活力和亡测定验证了UBE2N的致癌作用.
主要成果:
- UBE2N被确定为LUAD的独立预后生物标志物,其高表达与较低的存活率和晚期相关.
- 与增强的瘤细胞周期,DNA复制和氧化酸化相关的高UBE2N表达.
- 低UBE2N表达与内免疫细胞 (NK,树突细胞,T细胞) 的增加以及抗原呈现的改善相关.
- UBE2N过度表达预测免疫治疗和向治疗的反应不佳,这表明它在免疫逃避和药物耐药性方面发挥了作用.
- 抑制了LUAD细胞活力和诱导了细胞亡.
结论:
- UBE2N作为预后生物标志物和LUAD的治疗标具有前景.
- 抑制UBE2N可能会抑制LUAD的进展并提高治疗效率.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...